P3 Health Partners (PIII) Q2 2026 Earnings Call Transcript
P3 Health Partners (PIII) reported Q2 2026 adjusted EBITDA of $54.4 million versus a prior-year loss, on total revenue of $386.4 million (+9% YoY). At-risk membership fell 10% to 105,000. Net income was $15.7 million. The company raised full-year 2026 guidance to adjusted EBITDA of $80 million to $110 million and revenue of $1.5 billion to $1.6 billion.
How this was made
The 30-second read
Why it matters
The transcript highlights a shift toward more predictable earnings, with improved payer economics, lower medical cost trend versus the 2025 baseline, and a raised 2026 adjusted EBITDA outlook.
Market read
Traders can update valuation and positioning based on the raised full-year adjusted EBITDA range and the disclosed improvement in underlying profitability and medical cost trend.
What to watch
At-risk membership fell 10% while revenue rose 9%, so investors may scrutinize whether growth is sustainable without further membership changes or settlement tailwinds.
Background
P3 Health Partners is a Medicare-focused healthcare services company that reports results using adjusted EBITDA and underlying medical margin metrics tied to capitated revenue and medical cost trends.
Ticker impact
P3 Health Partners reported Q2 2026 revenue of $386.4M, adjusted EBITDA of $54.4M, and raised full-year 2026 adjusted EBITDA guidance to $80M-$110M.
Near-term bias higher as traders price in the raised 2026 adjusted EBITDA range and improved medical cost trend.
The call discloses multiple decision-relevant datapoints: net income improvement, underlying adjusted EBITDA turning positive, and explicit full-year guidance ranges, which typically drive earnings revisions and sentiment.
Market effects
Reinforces the managed-care services narrative that operational discipline and payer economics can stabilize earnings even with membership rationalization.
Nebraska expansion plan (services in 2027, full-risk in 2028) may affect local provider network expectations.
Limited, as the disclosure is company-specific within US Medicare Advantage care delivery.
Counterpoint
A large portion of reported profitability is supported by payer settlements and prior-year development, which may not recur at the same magnitude.
Key entities
- companyP3 Health Partners
Reported Q2 2026 results and raised full-year 2026 adjusted EBITDA guidance; discussed underlying profitability and medical cost trend drivers.
- executiveAric Coffman
CEO who attributed results to structural and operational contract, market, and operating-model changes.
- executiveLeif Pedersen
Commented on seasonal medical expense trends and stated the core business is generating positive adjusted EBITDA excluding settlements.
